Vesicant Extravasation Part II: Evidence-Based Management and Continuing Controversies
Purpose/Objectives: To review the literature, synthesize current recommendations, and discuss remaining controversies regarding vesicant extravasation management.
Data Sources: Published evidence-based reports, clinical articles, and anecdotal case reports about antineoplastic and nonantineoplastic vesicant agent management.
Data Synthesis: Prevention of vesicant extravasation sequelae requires knowledge about vesicant extravasation manifestations and differentiation of vesicant extravasation from other local IV site reactions. When evidence is weak or missing, logical application of data-based or empirical management strategies is critical. Actions may include timely administration of subcutaneous or topical antidotes, comfort measures, and surgical interventions to minimize the extent of tissue damage and morbidity should extravasation occur.
Conclusions: Vesicant extravasation and sequelae constitute a complex patient problem. Clinicians should strive to prevent extravasation or seek to minimize injury should it occur. To this end, clinicians must demonstrate awareness of its risks and use specialized knowledge when administering vesicant agents.
Implications for Nursing: Nurses who administer vesicant agents should understand the nursing and collaborative actions that should be taken to minimize patient morbidity, pain, and disability.
Jump to a section
References
Anderson, C., Walters, R., & Hortobagyi, G. (1996). Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early breast cancer. American Journal of Clinical Oncology, 19, 566-568.
Bertelli, G., Dini, D., Forno, G.B., Gozza, A., Silvestro, S., Venturini, M., et al. (1994). Hyaluronidase as an antidote to extravasation of vinca alkaloids: Clinical results. Journal of Cancer Research and Clinical Oncology 120, 505-506.
Bertelli, G., Gozza, A., Forno, G.B., Vidili, M.G., Silvestro, S., Venturini, M., et al. (1995). Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. Journal of Clinical Oncology, 13, 2851-2855.
Bos, A.M., van der Graaf, W.T., & Willemse, P.H. (2001). A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane. Acta Oncologica, 40, 541-542.
Boyle, D.M., & Engelking, C. (1995). Vesicant extravasation: Myths and realities. Oncology Nursing Forum, 22, 57-67.
Bozkurt, A.K., Uzel, B., Akman, C., Ozguroglu, M., & Molinas Mandel, N. (2003). Intrathoracic extravasation of antineoplastic agents: Case report and systematic review. American Journal of Clinical Oncology, 26, 121-123.
Curran, C.F., & Luce, J.K. (1990). Extravasation of doxorubicin from vascular access devices. Selective Cancer Therapeutics, 6, 103-107.
Curran, C.F., Luce, J.K., & Page, J.A. (1990). Doxorubicin-associated flare reactions. Oncology Nursing Forum, 17, 387-389.
Davies, A.G., Russell, W.C., & Thompson, J.P. (2003). Extravasation and tissue necrosis secondary to central line infusions. Anaesthesia, 58, 820-821.
Dorr, R.T. (1990). Antidotes to vesicant chemotherapy extravasations. Blood Reviews, 4, 41-60.
El Saghir, N.S., & Otrock, Z.K. (2004). Docetaxel extravasation into the normal breast during breast cancer treatment. Anticancer Drugs, 15, 401-404.
Ener, R.A., Meglathery, S.B., & Styler, M. (2004). Extravasation of systemic hemato-oncological therapies. Annuals of Oncology, 15, 858-862.
Fenchel, K., & Karthaus, M. (2000). Cytoxic drug extravasation. Antibiotics and Chemotherapy, 50, 144-148.
Foo, K.F., Michael, M., Toner, G., & Zalcberg, J. (2003). A case report of oxaliplatin extravasation [Letter]. Annals of Oncology, 14, 961-962.
Giunta, R. (2004). Early subcutaneous wash-out in acute extravasations [Letter]. Annals of Oncology, 15, 1146.
Goodman, M., & Peterson, J. (1997). Tips for administering chemotherapy. In R.A. Gates & R.M. Fink (Eds.), Oncology nursing secrets (pp. 45-55). Philadelphia: Hanley and Belfus.
Goodman, M., & Riley, M. (1997). Chemotherapy: Principles of administration. In S. Groenwald, M. Hansen Frogge, M. Goodman, & C. Henke Yarbro (Eds.), Cancer nursing principles and practice (4th ed., pp. 317-384). Sudbury, MA: Jones and Bartlett.
Heitmann, C., Durmus, C., & Ingianni, G. (1998). Surgical management after doxorubicin and epirubicin extravasation. Journal of Hand Surgery (British and European Volume), 23, 666-668.
Jensen, J.N., Lock-Andersen, J., Langer, S.W., & Mejer, J. (2003). Dexrazoxane—A promising antidote in the treatment of accidental extravasation of anthracyclines. Scandinavian Journal of Plastic and Reconstructive Surgery, Hand Surgery, 37, 174-175.
Kretzchmar, A., Pink, D., Thuss-Patience, P., Dorken, B., Reichert, P., & Eckert, R. (2003). Extravasations of oxaliplatin. Journal of Clinical Oncology, 21, 4068-4069.
Langer, S.W., Sehested, M., & Jensen, P.B. (2000). Treatment of anthracycline extravasation with dexrazoxane. Clinical Cancer Research, 6, 3680-3686.
Langer, S.W., Thougaard, A.V., Sehested, M., & Jensen, P.B. (2006). Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemotherapy and Pharmacology, 57, 125-128.
Langstein, H.N., Duman, H., Seelig, D., Butler, C.E., & Evans, G.R. (2002). Retrospective study of the management of chemotherapeutic extravasation injury. Annals of Plastic Surgery, 49, 369-374.
Loth, T.S., & Eversmann, W.W. (1991). Extravasation injuries in the upper extremity. Clinical Orthopaedics and Related Research, 272, 248-254.
Luke, E. (2005). Mitoxantrone-induced extravasation. Oncology Nursing Forum, 32, 27-29.
Meehan, J.L., & Sporn, J.R. (1994). Case report of Taxol administration via central vein producing a recall reaction at a site of prior Taxol extravasation [Letter]. Journal of the National Cancer Institute, 16, 1250-1251.
Muir, M. (1996). DMSO: Many uses, much controversy. Alternative and Complementary Therapies, July/August, 230-235. Retrieved June 6, 2005, from http://www.dmso.org/articles/information/pmuir.htm
Olver, I.N., Aisner, J., Hament, A., Buchanan, L., Bishop, J.F., & Kaplan, R.S. (1988). A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. Journal of Clinical Oncology, 6, 1732-1735.
Patel, J.S., & Krusa, M. (1999). Distant and delayed mitomycin C extravasation. Pharmacotherapy, 19, 1002-1005.
Polovich, M., White, J., & Kelleher, L. (Eds.). (2005). Chemotherapy and biotherapy guidelines and recommendations for practice (2nd ed.). Pittsburgh, PA: Oncology Nursing Society.
Rospond, R.M., & Engel, L.M. (1993). Dimethyl sulfoxide for treating anthracycline extravasation. Clinical Pharmacy, 12, 560-561.
Rudolph, R., & Larson, D.L. (1987). Etiology and treatment of chemotherapeutic agent extravasation injuries: A review. Journal of Clinical Oncology, 5, 1116-1126.
Schrijvers, D.L. (2003). Extravasation: A dreaded complication of chemotherapy. Annals of Oncology, 14(Suppl. 3), 26-30.
Schulmeister, L., & Camp-Sorrell, D. (2000). Chemotherapy extravasation from implanted ports. Oncology Nursing Forum, 27, 531-538.
Schummer, W., Schummer, C., Bayer, O., Muller, A., Bredle, D., & Karzai, W. (2005). Extravasation injury in the perioperative setting. Anesthesia and Analgesia, 100, 722-727.
Scuderi, N., & Onesti, M.G. (1994). Antitumor agents: Extravasation, management, and surgical treatment. Annals of Plastic Surgery, 32, 39-44.
Shapiro, J., & Richardson, G.E. (1994). Paclitaxel-induced "recall" soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb [Letter]. Journal of Clinical Oncology, 12, 2237-2238.
Sorich, J., Taubes, B., Wagner, A., & Hochester, H. (2004). Oxaliplatin: Practical guidelines for administration. Clinical Journal of Oncology Nursing, 8, 251-256.
Steele, C.A. (2001). Extravasation. In J.M. Yasko (Ed.), Nursing management of symptoms associated with chemotherapy (5th ed., pp. 247-270). West Conshohocken, PA: Meniscus Health Care Communications.
Vargel, I., Erdem, A., Ertoy, D., Pinar, A., Erk, Y., Altundag, M.K., et al. (2002). Effects of growth factors on doxorubicin-induced skin necrosis: Documentation of histomorphological alterations and early treatment by GM-CSF and G-CSF. Annals of Plastic Surgery, 49, 646-653.
Viale, P.H. (2003). Complications associated with implantable vascular access devices in the patient with cancer. Journal of Infusion Nursing, 26, 97-102.
Wickham, R. (1989). Extravasation from venous access devices. Outpatient Chemotherapy, 3, 3-4, 8, 10-11.
Wickham, R., Purl, S., & Welker, D. (1992). Long-term central venous catheter: Issues for care. Seminars in Oncology Nursing, 8, 133-147.
Wilkes, G.M. (2005). Therapeutic options in the management of colon cancer: 2005 update. Clinical Journal of Oncology Nursing, 9, 31-44.